HC Wainwright Estimates Precigen’s Q3 Earnings (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) – Analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for Precigen in a report issued on Thursday, March 26th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $0.00 per share for the quarter, up from their previous estimate of ($0.01). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.22 EPS, FY2028 earnings at $0.44 EPS, FY2029 earnings at $0.69 EPS and FY2030 earnings at $1.02 EPS.

Precigen (NASDAQ:PGEN) last posted its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.09. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%.The company had revenue of $4.57 million for the quarter, compared to analyst estimates of $8.29 million.

Several other research firms also recently weighed in on PGEN. Citizens Jmp raised their target price on shares of Precigen from $8.00 to $9.00 and gave the company a “market outperform” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Precigen from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.50.

Precigen Price Performance

Precigen stock opened at $3.67 on Friday. Precigen has a 52 week low of $1.11 and a 52 week high of $5.47. The company has a quick ratio of 3.95, a current ratio of 3.09 and a debt-to-equity ratio of 4.46. The firm’s 50-day simple moving average is $4.08 and its 200 day simple moving average is $3.98. The firm has a market capitalization of $1.30 billion, a PE ratio of -2.74 and a beta of 1.10.

Hedge Funds Weigh In On Precigen

Several institutional investors have recently added to or reduced their stakes in PGEN. Lansing Street Advisors acquired a new stake in Precigen in the 3rd quarter worth about $1,800,000. Patient Capital Management LLC increased its stake in shares of Precigen by 62.6% during the 3rd quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company’s stock valued at $87,056,000 after acquiring an additional 10,192,107 shares during the last quarter. Diametric Capital LP acquired a new position in shares of Precigen during the 2nd quarter valued at about $476,000. Boxer Capital Management LLC purchased a new position in shares of Precigen during the 3rd quarter worth about $2,796,000. Finally, AXQ Capital LP acquired a new stake in shares of Precigen in the fourth quarter worth approximately $106,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (Q3‑2026 to FY2030) and reiterated a Buy rating with a $10 price target, projecting material earnings improvement through 2030 — supportive for longer‑term upside.
• Positive Sentiment: Citizens/JMP lifted its price target to $9 and moved to “market outperform,” adding another near‑term bullish analyst signal. Benzinga coverage
• Positive Sentiment: Management says PAPZIMEOS launch is accelerating with broad U.S. payer coverage and expects Q1 revenue to exceed $18M; company guidance points toward cash‑flow breakeven in 2026 if momentum continues. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates…
• Positive Sentiment: Analyst write‑ups highlight PAPZIMEOS’s blockbuster potential and model scenarios that imply meaningful upside from current levels, underpinning buy‑side interest. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Q4 earnings materials and call transcripts are available for investors to parse execution details and commercial cadence; management commentary will drive near‑term sentiment. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Q4 beat on EPS (small) but revenue missed estimates — mixed fundamentals that leave room for both upside on commercial execution and downside if sales growth stalls. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: After a roughly 145% one‑year surge, some coverage questions valuation and whether near‑term upside is already priced in — pieces asking “Is it too late?” amplify profit‑taking pressure. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
• Negative Sentiment: High trading volume and short‑term pullback risk: elevated turnover after the rally can accelerate declines if upcoming sales data or payer dynamics disappoint — the main near‑term risk for the stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.